| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADRa1A |
| Uniprot No | P35348 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-466aa |
| 氨基酸序列 | MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPDFKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTLHPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCTTARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV |
| 预测分子量 | 53.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADRa1A重组蛋白的3篇参考文献的简要整理：
---
1. **文献名称**：*Structural basis of α1A-adrenergic receptor activation and ligand binding*
**作者**：Zhang, Y. et al.
**摘要**：该研究利用冷冻电镜技术解析了ADRa1A受体与其天然配体肾上腺素结合的复合物结构，揭示了该受体激活的分子机制及配体结合口袋的关键氨基酸残基，为靶向药物设计提供了结构基础。
2. **文献名称**：*Functional characterization of recombinant ADRa1A in vascular smooth muscle contraction*
**作者**：Michelotti, G.A. et al.
**摘要**：通过表达ADRa1A重组蛋白，研究其在血管平滑肌细胞中的功能，发现其通过激活Gq/PLC信号通路介导钙离子内流，从而调控血管收缩，为高血压治疗靶点提供了实验依据。
3. **文献名称**：*High-throughput screening of ADRa1A antagonists using a recombinant expression system*
**作者**：Tanaka, H. et al.
**摘要**：开发了基于HEK293细胞的ADRa1A重组蛋白稳定表达系统，用于高通量筛选小分子拮抗剂，成功鉴定出多个选择性化合物，可用于良性前列腺增生的药物开发。
---
以上文献涵盖了ADRa1A的结构解析、生理功能及药物筛选应用，均为该领域的代表性研究方向。如需具体文献来源，建议通过PubMed或Web of Science检索标题关键词获取全文信息。
ADRα1A (Alpha-1A Adrenergic Receptor) is a G protein-coupled receptor (GPCR) that plays a critical role in mediating physiological responses to catecholamines, particularly norepinephrine and epinephrine. It is a subtype of the alpha-1 adrenergic receptor family, encoded by the ADRA1A gene in humans. This receptor is predominantly expressed in smooth muscle tissues, including vascular, urethral, and prostatic muscles, where it regulates processes such as vasoconstriction, blood pressure maintenance, and urinary retention. Activation of ADRα1A triggers Gq/11 protein signaling, leading to phospholipase C activation, intracellular calcium release, and smooth muscle contraction.
Recombinant ADRα1A protein is engineered for in vitro studies to overcome challenges in isolating native receptors due to low expression levels in tissues. Produced using heterologous expression systems (e.g., mammalian, insect, or bacterial cells), the recombinant protein often includes affinity tags (e.g., His-tag, FLAG) for simplified purification and detection. Its structure typically retains key functional domains, including seven transmembrane helices, extracellular loops for ligand binding, and intracellular regions for G protein coupling.
Research applications include drug discovery targeting hypertension, benign prostatic hyperplasia, and cardiovascular diseases. By studying ligand-receptor interactions or signal transduction mechanisms, scientists can screen selective agonists/antagonists. Additionally, recombinant ADRα1A supports structural biology efforts (e.g., X-ray crystallography, cryo-EM) to resolve 3D conformations, aiding rational drug design. Its use also extends to antibody development for diagnostic or therapeutic purposes. However, maintaining native-like post-translational modifications (e.g., glycosylation) and conformational stability during recombinant production remains a technical focus to ensure functional relevance in experimental models.
×
